A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 18, 2019

Primary Completion Date

December 11, 2020

Study Completion Date

December 11, 2020

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

Frespaciguat

Single inhaled dose of frespaciguat 120, 165, 240, 300, 360, or 480 ug depending upon randomization

DRUG

Placebo

Single inhaled dose of placebo to match frespaciguat

Trial Locations (1)

Republican Clinical Hospital of Moldova ( Site 0001), Chisinau

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03744637 - A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002) | Biotech Hunter | Biotech Hunter